Volume 3.10 | Mar 16

Prostate Cell News 3.10 March 16, 2012
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
The Receptor Tyrosine Kinase Axl Is an Essential Regulator of Prostate Cancer Proliferation and Tumor Growth and Represents a New Therapeutic Target
Deregulation of the receptor tyrosine kinase Axl has been implicated in the progression of several human cancers. In this report, scientists identified Axl as a new therapeutic target for prostate cancer. [Oncogene] Abstract

View Nature.com Webcast: Current Controversies - HIV Vaccines
PUBLICATIONS (Ranked by Impact Factor of the Journal)


Interactions of Abiraterone, Eplerenone and Prednisolone with Wild-Type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
Abiraterone, a rationally-designed inhibitor of CYP17A1 recently approved for the treatment of docetaxel-treated castration-resistant prostate cancer, is often effective, but requires co-administration with glucocorticoids to curtail side effects. Here, researchers hypothesized that progressive disease on abiraterone may occur secondary to glucocorticoid-induced activation of mutated androgen receptor. [Cancer Res] Abstract

Central Role for Proline-, Glutamic Acid-, and Leucine-Rich Cofactor Protein 1 in Nonandrogenic Activation of the Androgen Receptor in Prostate Cancer
Here, researchers show the predominant estrogen receptor (ER) isoform expressed in prostate cancer specimens and cell lines is ERß. [Mol Endocrinol] Abstract

Targeting Bone Remodeling by Isoflavone and 3,3′-Diindolylmethane in the Context of Prostate Cancer Bone Metastasis
In this study, researchers found that prostate cancer cells could stimulate differentiation of osteoclasts and osteoblasts through the up-regulation of RANKL, RUNX2 and osteopontin, promoting bone remodeling. [PLoS One] Abstract

Resveratrol Enhances Radiation Sensitivity in Prostate Cancer by Inhibiting Cell Proliferation and Promoting Cell Senescence and Apoptosis
In this study, the effect of radiation therapy in combination with the radiosensitizing agent resveratrol was investigated in a radioresistant prostate cancer cell line, PC-3. [Cancer Sci] Abstract

Therapeutic Targeting of Angiotensin II Receptor Type 1 to Regulate Androgen Receptor in Prostate Cancer
Recent studies have demonstrated that an angiotensin II receptor blocker (ARB) has the potential to decrease serum prostate-specific antigen level and improve performance status in castration-resistant prostate cancer patients. These facts prompted researchers to investigate the direct effects of ARBs on prostate cancer growth and progression. [Prostate] Abstract

Role of Dutasteride in Pre-Clinical ETS Fusion-Positive Prostate Cancer Models
Here, researchers evaluated the expression levels of 5α-reductase isoenzymes in prostate cancer cell lines and tissues. They also tested the effect of dutasteride, a 5α-reductase inhibitor, in TMPRSS2ERG fusion-positive VCaP cell proliferation and cell invasion. [Prostate] Abstract

Peptides Binding to Prostate-Specific Antigen Enhance Its Antiangiogenic Activity
Researchers hypothesized that factors stimulating the activity of prostate-specific antigen (PSA) could be used to reduce prostate tumor growth. Here, their aim was to study whether these peptides enhance the antiangiogenic activity of PSA. [Prostate] Abstract

Novel Polypyridyl Chelators Deplete Cellular Zinc and Destabilize the X-Linked Inhibitor of Apoptosis Protein (XIAP) Prior to Induction of Apoptosis in Human Prostate and Breast Cancer Cells
In this study, researchers show that treatment of PC-3 prostate cancer and MDA-MB-231 breast cancer cells with membrane-permeable zinc-chelators with different zinc affinities results in varying degrees of XIAP depletion. [J Cell Biochem] Abstract


Prostate-Cancer Mortality at 11 Years of Follow-Up
Researchers updated prostate-cancer mortality in the European Randomized Study of Screening for Prostate Cancer with two additional years of follow-up. [N Engl J Med] Abstract | Press Release

Value of PET/CT and MR Lymphography in Treatment of Prostate Cancer Patients with Lymph Node Metastases
Researchers evaluated the ability of positron emission tomography (PET)/computed tomography (CT) and magnetic resonance (MR) lymphography to assess the number, size, and location of lymph node metastases in patients with primary or recurrent prostate cancer. [Int J Radiat Oncol Biol Phys] Abstract

The Identification and Internal Validation of a Preoperative Serum Biomarker Panel to Determine Extracapsular Extension in Patients with Prostate Cancer
Researchers followed a biomarker development pathway and compared the preoperative serum expressions of VEGF-D, PEDF, IGF-I, IGFBP3, and CD14 in patients from the Irish Prostate Cancer Research Consortium with radical prostatectomy determined extracapsular extension (ECE) against patients with nonECE. [Prostate] Abstract

Watch the Video: Optimize Your ALDHbr Cell Detection with Tissue-Specific ALDEFLUOR™ Protocols


Renowned Prostate Cancer Researcher Receives the Amory Prize
Patrick Walsh received the prestigious Amory Prize award from the American Academy of Arts and Sciences. Dr. Walsh is widely-acclaimed as one of the world’s leading prostate cancer clinicians and researchers in the history of the field. [Prostate Cancer Foundation] Press Release

The Prostate Cancer Foundation Expands Global Reach, Adds First Two PCF Young Investigators in China
The Prostate Cancer Foundation (PCF) announced its first two Young Investigators in China to launch its initiative to identify, fund and promote innovative research projects within China. [Prostate Cancer Foundation] Press Release

Teva and OncoGenex Announce Updates to Custirsen Development Program in Advanced Prostate Cancer
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced an update on their development program for custirsen, a product candidate being evaluated in Phase III studies for castrate-resistant prostate cancer. [OncoGenex Pharmaceuticals, Inc.] Press Release

Prostate Cancer Canada Set to Lead the Way in Research
Prostate Cancer Canada announced that it has formed a Research Advisory Panel to best facilitate and aid in implementing a national research strategy. [Prostate Cancer Canada] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 9th Meeting of the EAU Section of Urological Oncology (ESOU)
April 20-22, 2012
Hamburg, Germany

NEW European Society for Radiotherapy & Oncology (ESTRO): Brachytherapy for Prostate Cancer
June 28-29, 2012
Lisbon, Portugal

Visit our events page to see a complete list of events in the prostate cell community.


Scientist – Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

PhD Position – Cell Biology/Infection Research (University of Münster)

Clinical Research Associate (Jennerex Biotherapeutics, Inc.)

Research Associate – Development (Precision Therapeutics, Inc.)

Postdoctoral Fellow (Louisiana State University Health Sciences Center) 

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us